Background
==========

Atrial fibrillation (AF), the most common arrhythmia, affected more than 33 million individuals in 2010 worldwide. It increases the burden of stroke, heart failure, cognitive decline, and mortality \[[@b1-medscimonit-25-8011],[@b2-medscimonit-25-8011]\]. Sex-related disparities in AF are increasingly acknowledged \[[@b3-medscimonit-25-8011]--[@b5-medscimonit-25-8011]\]. Western countries have reported that clinical presentations and quality of life (QoL) differed between women and men with AF \[[@b6-medscimonit-25-8011]--[@b8-medscimonit-25-8011]\], and women with AF seemed to be under-treated compared to men \[[@b8-medscimonit-25-8011]--[@b10-medscimonit-25-8011]\]. However, sex differences are not well-examined in Chinese AF patients.

The China AF Registry study is an ongoing prospective registry -- one of the largest for Asian AF patients. It will provide an excellent opportunity to evaluate this knowledge gap. A better understanding of the sex differences in AF may have important implications for quality improvement to reduce or even eliminate the sex disparities in AF care.

In this study, we used data from the China AF Registry to evaluate sex-related differences with the presentation, QoL, and treatment in Chinese AF patients.

Material and Methods
====================

The China AF Registry study is a prospective, multicenter, ongoing registry study of AF patients from 31 hospitals in Beijing, China. The design of the study had been published \[[@b11-medscimonit-25-8011]\]. Local ethics committee approval was obtained and all participants provided signed informed consent.

Study population
----------------

The China AF Registry study had enrolled 19 515 AF patients from August 2011 to December 2016. In this analysis, we excluded 546 patients with mitral stenosis or valvular surgery, 3380 patients without valid Atrial Fibrillation Effects on QualiTy of Life (AFEQT) questionnaires, and 866 patients without European Heart Rhythm Association (EHRA) classification data. Finally, we included 14 723 participants. [Figure 1](#f1-medscimonit-25-8011){ref-type="fig"} shows a flowchart of the study.

Data collection
---------------

Clinicians in participating hospitals collected data from medical charts. Collecting information included necessary socio-demographic data, AF type and duration, medical history, symptom and AFEQT questionnaires, and previous and current treatment. We defined variables according to the ACC/AHA recommendations on AF clinical data standards \[[@b12-medscimonit-25-8011]\].

AF symptoms and QoL evaluation
------------------------------

AF-related symptoms were evaluated using the EHRA AF symptom classification: no symptoms (EHRA I), mild symptoms (EHRA II), severe symptoms (EHRA III), and disabling symptoms (EHRA IV) \[[@b13-medscimonit-25-8011]\].

A Chinese version of the AFEQT questionnaire was collected to assess health-related quality of life (HRQoL) at baseline. The AFEQT questionnaire is an AF-specific QoL evaluation which was recently developed and validated, supporting its use as a self-administered outcome measure in studies and as a tool for disease management \[[@b14-medscimonit-25-8011]\]. The AFEQT questionnaire contains 20 questions to evaluate the influence of AF on patients' HRQoL during the past 4 weeks. The 18 items generate 3 individual subscales -- Symptoms, Daily Activities, and Treatment Concern. The last 2 indicate the Treatment Satisfaction domain. Overall AFEQT score is calculated based on the first 3 functional subscales. To be valid, the AFEQT questionnaires must have should at least half of the questions answered for each domain. AFEQT is scored with a 7-point Likert scale. The range of overall AFEQT or subscale scores is 0--100. Score 0 represents extremely disability and 100 indicates not at all limited. Thus, higher ratings indicate a better health status. For a percentage grading system of AFEQT scores, we set ≥60 as passing scores indicating a 'normal level' of QoL, and the lower score sections as mild impairment of QoL (AFEQT scores 40--59), moderate impairment of QoL (AFEQT scores 20--39) and severe impairment of QoL (AFEQT \<20).

Statistical analysis
--------------------

Continuous variables showed a mean±standard deviation or median (interquartile range); differences were assessed using the *t* test or Wilcoxon rank-sum test. Categorical variables are shown as numbers (percentages), and differences were compared using the chi-square test.

Multivariate logistic regression analysis was performed to assess the association between sex and QoL (the proportion of overall AFEQT score ≥60). We corrected variables with potential influence on QoL, including age, body mass index (BMI), medical insurance and education, smoking, comorbidities (heart failure, hypertension, diabetes, previous thromboembolism, vascular disease, hyperlipidemia, and renal dysfunction), AF type and duration, and current pharmacological treatments.

A two-tailed *P* value \<0.05 was considered statistically significant. We used SAS software 9.2 for data analyses.

Results
=======

Among 14 723 patients with AF included in this study, 5645 (38.3%) were women. [Table 1](#t1-medscimonit-25-8011){ref-type="table"} shows the characteristics of the patients. Since women were older on average by 5 years than men in the study (67.5±10.6 *vs.* 62.2±12.2, P\<0.0001), we stratified the patients by age\<75 and age ≥75 groups. In both age groups, women had higher rates of heart failure, hypertension, diabetes, and renal dysfunction, but a lower rate of vascular disease. Previous thromboembolism was similar according to sex in both 2 age groups. Paroxysmal AF (65.3% *vs.* 55.8%, *P*\<0.0001) and a CHA~2~DS~2~-VAS~C~ score ≥2 (82.2% *vs.* 45.3%, *P*\<0.0001) was more prevalent in women for those aged \<75 years.

AF-related symptoms
-------------------

Female AF patients experienced more severe or disabling symptoms, with a higher proportion of EHRA III and IV classification, than men (35.6% *vs.* 24.0%, *P*\<0.0001). Only 5.4% of women had no symptom, compared with 8.4% of men ([Figure 2](#f2-medscimonit-25-8011){ref-type="fig"}). Both age groups had similar results.

Quality of life
---------------

[Figure 3](#f3-medscimonit-25-8011){ref-type="fig"} summarizes the proportion of the overall and each subscale of AFEQT scores by sex and age. Women had a lower percentage of an average QoL level (AFEQT ≥60 scores) than men (54.1% *vs.* 66.7% in overall patients, 57.0% *vs.* 68.5% in age \<75 years group and 46.8% *vs.* 58.4% in those aged ≥75 years group, both *P*\<0.0001). The subscales of Symptoms, Daily Activities, and Treatment Concern all showed consistent results ([Figure 3](#f3-medscimonit-25-8011){ref-type="fig"}). We also compared the mean value of overall AFEQT and each subscale score by sex, type of AF, and CHA~2~DS~2~-VASc scores, as shown in [Figure 4](#f4-medscimonit-25-8011){ref-type="fig"}. Women had lower overall AFEQT scores than men in those aged \<75 years (59.6±15.0 *vs.* 64.4±14.2, *P*\<0.0001) and in older groups (57.5±15.1 *vs.* 61.2±15.3, *P*\<0.0001). In newly diagnosed, paroxysmal AF, or persistent AF, women had lower overall AFEQT scores than men (All *P* \<0.05 except for newly diagnosed AF in age ≥75 years group). Also, the AFEQT scores decreased in women across all CHA~2~DS~2~-VASc score groups. After the correction of demographics, comorbidities, and pharmacological treatments, female sex remained independently associated with lower overall AFEQT score (OR 0.69; 95%CI, 0.63--0.76; P\<0.0001).

AF-related treatment
--------------------

We found no sex disparity in the prior use of electrical cardioversion ([Table 2](#t2-medscimonit-25-8011){ref-type="table"}). Women tended to receive less AF ablation (5.7% *vs.* 6.7%, *P*=0.025) in those aged \<75 years, but not in patients age ≥75 years (2.0% *vs.* 2.0%, *P*=0.949). In the group age \<75, women were more likely to receive the rate control (51.4% *vs.* 46.9%, *P*\<0.0001), but fewer received rhythm-control drugs (35.5% *vs.* 39.8%, *P*\<0.0001). However, in the elderly group, current rhythm-control drug use had no significant difference between women and men (20.2% *vs.* 20.9%, *P*=0.664), while women still were more likely to receive rate control therapy (65.2% *vs.* 59.3%, *P*=0.001). Both women and men with CHA~2~DS~2~-VASc score ≥2 had low rates of oral anticoagulant (OAC) use (32.1% *vs.* 30.1% in those aged \<75, P=0.081; and 34.6% *vs.* 35.3% in those aged ≥75, P=0.700).

Discussion
==========

This massive Chinese AF cohort study indicated that women with AF tended to be older, with more comorbidities and more severe symptoms. After adjustment, women had lower QoL than men. Moreover, despite being much more likely to be symptomatic, women tended to receive less rhythm-control treatment in those aged \<75. OAC use was low and had no sex difference in high stroke risk AF patients.

Prior extensive cohort studies have shown sex disparities in clinical features, treatment, and outcomes of AF in Western countries \[[@b6-medscimonit-25-8011],[@b7-medscimonit-25-8011]\]. Female AF patients tended to be older, and were more likely to have a high burden of hypertension and heart failure with a preserved ejection fraction \[[@b15-medscimonit-25-8011]\]. However, few studies have reported the association between sex and symptoms burden and QoL \[[@b8-medscimonit-25-8011],[@b16-medscimonit-25-8011],[@b17-medscimonit-25-8011]\]. In a European survey, the EORP-AF study, women were found to have more symptoms, including palpitations, fear, and anxiety \[[@b7-medscimonit-25-8011]\]. A systematic review suggested that asymptomatic AF was less common among women than among men \[[@b18-medscimonit-25-8011]\]. A Europe survey reported that women had a lower general QoL using EuroQol scores \[[@b8-medscimonit-25-8011]\]. The ORBIT-AF registry \[[@b6-medscimonit-25-8011]\], a US-based observational study, has demonstrated that female AF patients had more significant impairment of HRQoL as measured by specific AFEQT scores. Such sex differences were consistent with our large cohort study of Chinese AF patients, and a recently published systemic review has confirmed this \[[@b19-medscimonit-25-8011]\]. The physical and psychosomatic characteristics of female patients may be related to the observed differences in clinical characteristics and presentation \[[@b20-medscimonit-25-8011]--[@b24-medscimonit-25-8011]\]. Older age may also contribute to the differences in comorbidities, since women were older by an average of 5 years compared with men \[[@b20-medscimonit-25-8011]\]. However, the differences in QoL were still significant after multivariable adjustment.

Guidelines indicate rhythm-control therapy to improve the symptom of AF patients (Class I, level B) \[[@b25-medscimonit-25-8011]\]. In our study, younger (age \<75) female AF patients were treated more conservatively with less catheter ablation or antiarrhythmic drugs than men, despite having a higher proportion of paroxysmal AF, more severe AF-related symptoms, and worse QoL. The ORBIT-AF study did not find sex-specific differences in the use of antiarrhythmic drugs \[[@b6-medscimonit-25-8011]\], but women tended to receive less electric cardioversion or ablation therapy. The EORP-AF study reported similar differences in treatment \[[@b7-medscimonit-25-8011]\]. Women with symptomatic AF received less rhythm-control treatment, and we observed the same treatment pattern in asymptomatic patients.

Nevertheless, these studies did not adjust for some critical factors, including age, comorbidities, duration, and symptom burden of AF. The reasons for the disparities remain mostly unknown, and potential explanations include sex differences in patient preferences and other clinical and socioeconomic factors \[[@b26-medscimonit-25-8011]\]. Age may play an essential role in treatment strategy referral \[[@b15-medscimonit-25-8011]\]. In our study, there was no sex-specific difference in rhythm-control treatment for patients ≥75 years. The efficacy and safety of antiarrhythmic drugs for women may influence the treatment preferences \[[@b27-medscimonit-25-8011]--[@b29-medscimonit-25-8011]\]. In addition, women tended to be less educated and less covered by health insurance than men in our study. Thus, they may be more likely to delay seeking medical care and to accept more conservative treatment than men.

Our study observed that OAC for preventing stroke in high-risk patients was substantially underused regardless of sex, and women received OAC use similarly to men. Previous substantial worldwide cohort research reported no sex differences in the use of OAC \[[@b30-medscimonit-25-8011],[@b31-medscimonit-25-8011]\]. The EORP-AF and ORBIT-AF study found similar results \[[@b6-medscimonit-25-8011], [@b7-medscimonit-25-8011]\]. However, in another outpatient AF cohort, with a CHA~2~DS~2~-VASc score ≥2, women were associated with less frequent prescription of OAC \[[@b32-medscimonit-25-8011]\]. Although the previous research suggested that female sex is not an independent risk factor of thromboembolism \[[@b33-medscimonit-25-8011]\], women had poorer long-term outcomes among stroke survivors \[[@b34-medscimonit-25-8011],[@b35-medscimonit-25-8011]\]. The extensive treatment gap in OAC use for stroke prevention remains in Chinese AF patients of both sexes. Therefore, great efforts are warranted to promote OAC therapy among high-risk patients with AF in China.

Limitations
-----------

First, the China AF Registry is a hospital-based registry; thus, patient selection bias is possible. Women may tend to not seek medical help until they experienced severe symptoms and significantly impaired QoL. However, these patients are representative of the patients we meet in clinical practice and thus are clinically relevant. Second, participating hospitals in this study are in Beijing, China's capital; however, about half of the participants came from all over the country, thus increasing the population samples' representativeness. Finally, statistical methods cannot adequately correct for residual or unmeasured confounders in a registry study.

Conclusions
===========

In this prospective Chinese Registry, women with AF tended to be older, with more comorbidities, and had more severe symptoms and poorer QoL, compared to men. Despite all these factors, women tended to receive less rhythm-control treatment than men in those aged \<75 years. OAC was substantially underused in high stroke risk patients regardless of sex.
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![Flowchart of patients included. AF -- atrial fibrillation; AFEQT -- Atrial Fibrillation Effects on QualiTy of Life; EHRA = European Heart Rhythm Association.](medscimonit-25-8011-g001){#f1-medscimonit-25-8011}

![Proportions of each EHRA classification by Sex. European Heart Rhythm Association (EHRA) AF symptoms classification was defined as no symptoms (EHRA I), mild symptoms (EHRA II), severe symptoms (EHRA III), and disabling symptoms (EHRA IV). F -- Female; M -- Male. \* P\<0.0001, Female *vs.* Male.](medscimonit-25-8011-g002){#f2-medscimonit-25-8011}

![Proportions of each section in overall AFEQT and subscales scores by sex. AFEQT scores were classified as 4 sections: normal level of QoL (AFEQT scores ≥60), mild impairment of QoL (AFEQT scores 40\~59), moderate impairment of QoL (AFEQT scores 20\~39), and severe impairment of QoL (AFEQT \<20). (**A**) Overall patients; (**B**) Patients aged \<75 years old; (**C**) Patients aged ≥75 years old. AFEQT -- Atrial Fibrillation Effects on QualiTy of Life; SY -- symptoms; DA -- daily activities; TC -- treatment concern; TS -- treatment satisfaction; F -- Female; M -- Male. \* P\<0.0001, \*\* P=0.025, \*\*\* P=0.01, Female *vs.* Male.](medscimonit-25-8011-g003){#f3-medscimonit-25-8011}

![Mean overall AFEQT and subscales scores by sex and type of AF and CHA~2~DS~2~-VAS~C~ Scores between females and males. (**A**) Mean overall AFEQT and subscales scores by sex; (**B**) Mean overall AFEQT and subscales scores by sex and type of AF. (**C**) Mean overall AFEQT and subscales scores by sex and CHA~2~DS~2~-VAS~C~ scores. AFEQT -- Atrial Fibrillation Effects on QualiTy of Life; SY -- symptoms; DA -- daily activities; TC -- treatment concern; TS -- treatment satisfaction. \* P\<0.0001, \*\* P\<0.05, Female *vs.* Male.](medscimonit-25-8011-g004){#f4-medscimonit-25-8011}

###### 

Baseline characteristics according to sex and age.

  Characteristics               Age \<75 (N=11515)   Age ≥75 (N=3208)                                                        
  ----------------------------- -------------------- ------------------ -------------- ------------------ ------------------ --------------
  Age (years)                   62.8±8.6             58.5±10.1          **\<0.0001**   79.5±3.8           79.2±4.0           **0.068**
  Health insurance coverage                                                                                                  
   None                         300/4053 (7.4)       512/7462 (6.9)     **\<0.0001**   95/1592 (6.0)      65/1616 (4.0)      **\<0.0001**
   Low                          1729/4053 (42.7)     2510/7462 (33.6)                  781/1592 (49.1)    673/1616 (41.7)    
   High                         2024/4053 (49.9)     4440/7462 (59.5)                  716/1592 (45.0)    878/1616 (54.3)    
  Completed high school         839/3824 (21.9)      2875/7109 (40.4)   **\<0.0001**   320/1411 (22.7)    548/1441 (38.0)    **\<0.0001**
  BMI                           25.6±4.0             25.9±3.4           **\<0.0001**   24.6±4.0           24.2±3.3           **0.001**
  Smoking                       76/4042 (1.9)        2244/7441 (30.2)   **\<0.0001**   41/1579 (2.6)      179/1605 (11.2)    **\<0.0001**
  Drinking                      60/4045 (1.5)        2832/7428 (38.1)   **\<0.0001**   17/1578 (1.1)      277/1605 (17.3)    **\<0.0001**
  Medical History                                                                                                            
   Heart failure                502/4053 (12.4)      746/7462 (10.0)    **\<0.0001**   561/1592 (35.2)    472/1615 (29.2)    **0.0003**
   Hypertension                 2651/4052 (65.4)     4135/7458 (55.4)   **\<0.0001**   1319/1589 (83.0)   1215/1615 (75.2)   **\<0.0001**
   Diabetes mellitus            987/4052 (24.4)      1611/7460 (21.6)   **0.001**      526/1592 (33.0)    454/1615 (28.1)    **0.002**
   Previous stroke/TIA/SE       550/4051 (13.6)      993/7455 (13.3)    **0.699**      397/1589 (25.0)    424/1614 (26.3)    **0.405**
   Vascular disease             520/4050 (12.8)      1059/7455 (14.2)   **0.042**      398/1588 (25.1)    458/1612 (28.4)    **0.032**
   Previous bleeding            170/4051 (4.2)       321/7455 (4.3)     **0.782**      101/1589 (6.4)     114/1613 (7.1)     **0.421**
   Hyperlipidemia               1290/4043 (31.9)     2075/7448 (27.9)   **\<0.0001**   602/1587 (37.9)    477/1608 (29.7)    **\<0.0001**
   eGFR \<60 mL/min/1.73 m^2^   110/3180 (3.5)       79/5919 (1.3)      **\<0.0001**   185/1308 (14.1)    111/1317 (8.4)     **\<0.0001**
  AF type                                                                                                                    
   Newly diagnosed              232/4050 (5.7)       286/7455 (3.8)     **\<0.0001**   151/1591 (9.5)     151/1616 (9.3)     **0.528**
   Paroxysmal                   2643/4050 (65.3)     4163/7455 (55.8)                  774/1591 (48.7)    757/1616 (46.8)    
   Persistent                   1175/4050 (29.0)     3006/7455 (40.3)                  666/1591 (41.9)    708/1616 (43.8)    
  AF duration (years)           2.4 (0.6--5.7)       2.5 (0.7--6.0)     **0.052**      3.0 (0.8--7.3)     3.6 (1.0--9.0)     **0.001**
  CHA~2~DS~2~-VASC                                                                                                           
   0 or 1                       722/4050 (17.8)      4073/7452 (54.7)   **\<0.0001**   0                  0                  --
   ≥2                           3328/4050 (82.2)     3379/7452 (45.3)                  1588/1588 (100)    1612/1612 (100)    

Values are n/N (%), mean±SD or median (IQR). Denominators may be subject to missing data. BMI -- body mass index; TIA -- transient ischemic attack; SE -- systemic embolism; eGFR -- estimated glomerular filtration rate; AF -- atrial fibrillation; IQR -- interquartile range; CHA~2~DS~2~-VASc -- cardiac failure or dysfunction, hypertension, age ≥75 years (doubled), diabetes mellitus, stroke (doubled)--vascular disease, age 65--74 years, and sex category (Female).

###### 

AF-related treatment stratified by sex and age.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment                                                                               Age \<75 (N=11515)\   Age ≥75 (N=3208)\                                                   
                                                                                          n (%)                 n (%)                                                               
  --------------------------------------------------------------------------------------- --------------------- -------------------- ---------- ----------------- ----------------- ----------
  Prior electrical cardioversion                                                          76 (1.9)              178 (2.4)            0.075      10 (0.6)          15 (0.9)          0.334

  Prior AF catheter ablation                                                              230 (5.7)             503 (6.7)            0.025      32 (2.0)          33 (2.0)          0.949

  Current rhythm-control drugs                                                            1437 (35.5)           2970 (39.8)          \<0.0001   332 (20.9)        327 (20.2)        0.664

   Propafenone                                                                            757 (18.7)            1213 (16.3)          0.001      108 (6.8)         116 (7.2)         0.661

   Amiodarone                                                                             564 (13.9)            1621 (21.7)          \<0.0001   157 (9.9)         171 (10.6)        0.501

   Sotalol                                                                                90 (2.2)              128 (1.7)            0.058      26 (1.6)          20 (1.2)          0.346

  Current rate control drugs                                                              2083 (51.4)           3502 (46.9)          \<0.0001   1038 (65.2)       959 (59.3)        0.001

   β-blocker                                                                              1921 (47.4)           3232 (43.3)          \<0.0001   895 (56.2)        807 (49.9)        \<0.0001

   Calcium-channel blockers                                                               199 (4.9)             270 (3.6)            0.001      138 (8.7)         107 (6.6)         0.029

   Digoxin                                                                                252 (6.2)             384 (5.1)            0.016      234 (14.7)        201 (12.4)        0.062

  [\*](#tfn3-medscimonit-25-8011){ref-type="table-fn"} Current OAC(CHA~2~DS~2~-VASC ≥2)   1002/3328 (30.1)      1084/3379 \|(32.1)   0.081      560/1588 (35.3)   558/1612 (34.6)   0.700
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are n (%), except where indicated.

Rates of current OAC are expressed as the number of patients received oral anticoagulant treatment divided by the number of patients who have indication for anticoagulation treatment (i.e., CHA~2~DS~2~-VAS~C~ ≥2).

AF -- atrial fibrillation; OAC -- oral anticoagulant; CHA~2~DS~2~-VASc -- cardiac failure or dysfunction, hypertension, age ≥75 years (doubled), diabetes mellitus, stroke (doubled)--vascular disease, age 65--74 years, and sex category (Female).
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